Home Politics Religion Media Biz Society Tech Travel Books Intl. Autos Automobiles
                        Aviation   Pharma   About Us   Feedback   Links

J&J's Concerta approved treatment of ADHD in teenagers in Canada



19th August, 2005: The Canadian health regulators have granted approved Concerta (methylphenidate HCl) Extended-release Tablets for use in adolescents (aged 13 to 18) with Attention Deficit Hyperactivity Disorder (ADHD). With the Health Canada's approval for extended indication, the drug can be now be continued through teenage years. Until now Concerta was approved for the treatment of ADHD in children aged six to 12 years. 

In a clinical study of adolescents aged 13 to 18 years, Concerta at doses up to 72 mg significantly reduced ADHD symptoms, such as difficulty paying attention to schoolwork. An effective once a day dose schedule will help with compliance and is very important for the adolescent. One-dose-per-day medications such as Concerta control symptoms of ADHD, take medication out of the classroom and minimize the 'ups and downs' in behaviour associated with multiple dosing, throughout the day, a press release from Johnson & Johnson said.

When children and adolescents with ADHD go untreated or are inadequately treated, they can be at risk for developing poor academic performance and poor social skills which can lead to more significant consequences later in life, including unemployment, criminal behaviour and substance misuse. 

In two Concerta studies, namely one study with children where the ADHD comparator medication was given three times a day and the other, a placebo-controlled study with adolescents, significantly more patients treated with once-a-day Concerta responded to treatment and achieved remission (i.e., normalization of function) compared to patients on the comparator medication or placebo. In the study for children, remission rates were 44 percent for those on Concerta compared to 16 per cent for those on the three times a day comparator medication. This research suggests that Concerta is associated with superior symptom control compared to older ADHD treatments.
Approximately four to 11 percent of school-aged children/adolescents are affected by ADHD which totals up to an estimated half million children/adolescents in Canada alone. ADHD is characterized by three core symptoms - inattention, hyperactivity and impulsivity. Inattention can include an inability to focus and pay attention or difficulty finishing tasks. The child is easily distracted. Hyperactivity can include fidgeting, talking excessively and a tendency to run around at inappropriate times or difficulty playing and engaging in leisure activities. Impulsivity can include difficulty awaiting turn and interrupting or intruding often on others.

Concerta is a once-daily extended-release formulation of methylphenidate. The efficacy of the drug has been demonstrated in studies conducted in children and adolescents. Only a doctor can determine if medication is the right treatment for individuals with ADHD.

Concerta uses an advanced OROS (hydromorphone) extended-release delivery system to deliver a controlled rate of medication throughout the day. Because of its unique OROS system, Concerta minimizes the ups and downs in blood levels experienced with stimulant medications taken several times a day.

The drug should not be taken by patients with: significant anxiety, tension or agitation; allergies to methylphenidate or other ingredients in Concerta; glaucoma, Tourette's syndrome, tics or family history of Tourette's syndrome; current/recent use of monoamine oxidase inhibitors (MAOIs). Abuse of methylphenidate may lead to dependence. Concerta should not be taken by children under six years of age.

In clinical studies with children using Concerta, the most common side effects were headache, stomach pain, sleeplessness and decreased appetite. In clinical studies with adolescents using Concerta, the most common side effects were headache, accidental injury and sleeplessness, the release added.

Concerta is marketed by Janssen-Ortho Inc a brand-name pharmaceutical company headquartered in Toronto with a broad range of medications used in attention deficit hyperactivity disorder, psychiatry, neurology, pain management, women's health, infectious disease, gastroenterology and urology.


Pharma News Headlines

Cancer News

Cardiac News


Pharma industry news

Diseases - Alzheimer's, Parkisonson's and Obesity

Contraception and Abortion News


Anti fungal terbinafine launched in Europe: Actavis

HIV entry blocking drug data encouraging: Progenics

Allegra generic to be launched in US

Long-acting pain drug data positive: Pain Therapeutics

New kidney cancer drug seeks EU nod

Inhaled insulin may get US FDA clearance

A vaccine against fungus is on way

Enzyme stops progression of HIV in survivors, confirms study

Aclasta found faster-acting in Paget's disease treatment

Beta blocker can start therapy in heart failure: Merck

Halobetasol generic launched in US

Anemia drug darbepoetin's late-stage studies begin: Amgen

Cholesterol generic gets marketing nod in US: Par

Aricept for severe Alzheimer’s disease too: Eisai

Bone regeneration trials begin in US:Mesoblast

New dye to detect early Alzheimer's

Breast forming gene discovered

Thyroid drug to be supplied by IVAX in US

Rituxan, cancer drug can treat rheumatoid arthritis

Yasminelle, low-dose oral contraceptive approved in the Netherlands

Fluarix, anti-flu shot by Glaxo approved

Increlex, drug to treat `abnormally short’ kids approved in US

Anti-HIV drugs prices cut: Gilead

US FDA approves Takeda’s drug combo for type 2 diabetes

Novartis’ drug for breast cancer recurrence to be given priority review in US

US puts off decision on contraceptive pill again

Shire’s ADHD drug Adderall back on list in Canada

WHO calls for emergency action to halt TB in Africa

Some of the Vioxx suits may be settled: Merck

Nasdaq delists Able on bankruptcy filing

Hospira ships ceftriaxone generics to US

Renovis stops sciatica drug studies

Merck sets up generic arm Genpharm in US

Morning after pills still not within easy reach in US

New cancer combo therapy results positive:OXiGENE

Aceon approved for heart disease treatment in US

Cell Therapeutics to seek approval for lung cancer therapy in US and Europe

Anti-depressant Seroxat defended by GSK against new findings

Vioxx verdict: Merck’s defeat to trigger thousands of lawsuits from US, UK

Aspirin stops colon cancer, but may trigger bleeding

New blood test method approved in US

Skin disease drug turns into anti-tumor therapy for cancer

Step-by-Step instructions for dealing with Asthma Attacks

Potential Alzheimer's Disease drugs under investigation

New Molecule may help obese lose weight

Paxil (Paroxetine) may heighten suicide risks, finds study

"Breast cancer chances higher due to fried chips"

Safety alert on Gambro Dasco’s Prisma renal system

Merck responsible for Vioxx death: Jury

Heart disease deaths more among New Yorkers

Pfizer to offer drugs risk/benefit summary to consumers 

Merck lied to public on Vioxx: lawyer tells jurors

Novartis acquires rights of kidney dialysis drug from SeBo

J&J's Concerta approved treatment of ADHD in teenagers in Canada

US FDA stalls Roche’ Accutane use in pregnancy

Novo Nordisk, Eli Lilly remove insulin products from Australia

British drug supply chain safety questioned after another fake Lipitor find

Wyeth starts support programme for Effexor patients

P&G’s Actonel with Calcium approved for osteoporosis

Pozen gets patent on pain management product

Genmab studies new drug for rheumatoid arthritis

Painkillers may increase blood pressure: study

Nektar buys out Aerogen for $32 m

Predix records positive data on anxiety drug

Insmed files against Increlex approval

Hepatitis A vaccine for kids approved in US

Psoriasis drug data positive: Cytochroma

Novo Nordisk’s 24-hour acting insulin Levemir gets US FDA okay

US FDA approves Teva's generic for osteoporosis 


Home Politics Religion Media Biz Society Tech Travel Books Intl. Autos Automobiles
                        Aviation   Pharma   About Us   Feedback   Links

Latest updates    Contact Us - Feedback    About Us